Yahoo
NYSE American - Delayed Quote USD

CEL-SCI Corporation (CVM)

1.5600 -0.0400 (-2.50%)
At close: August 28 at 4:00:00 PM EDT
1.5700 +0.0100 (+0.64%)
Pre-Market: 8:19:43 AM EDT
Chart Range Bar
Loading chart for CVM
  • Previous Close 1.6000
  • Open 1.6100
  • Bid 1.4700 x 30000
  • Ask 1.6300 x 20000
  • Day's Range 1.5300 - 1.6100
  • 52 Week Range 0.8900 - 12.6800
  • Volume 169,408
  • Avg. Volume 320,115
  • Market Cap (intraday) 27.439M
  • Beta (5Y Monthly) 0.56
  • PE Ratio (TTM) --
  • EPS (TTM) -1.6900
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Aug 28, 1996
  • 1y Target Est 12.50

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

cel-sci.com

--

Full Time Employees

September 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More
Cel-Sci: Fiscal Q1 Earnings Snapshot

Cel-Sci: Fiscal Q1 Earnings Snapshot

Performance Overview

Trailing total returns as of 8/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CVM
70.34%
S&P 500 (^GSPC)
12.65%

1-Year Return

CVM
83.24%
S&P 500 (^GSPC)
18.61%

3-Year Return

CVM
96.34%
S&P 500 (^GSPC)
73.95%

5-Year Return

CVM
99.52%
S&P 500 (^GSPC)
71.02%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY24
Revenue --
Earnings -6.11M
Profit Margin 0.00%

Q1

FY24

Q2

FY24

Q3

FY24

Q4

FY24

-6M
-4M
-2M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

10.00
12.50 Average
1.5600 Current
15.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 7/12/2023
Analyst EF Hutton
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 10

Statistics

View More

Valuation Measures

Annual
As of 8/27/2026
  • Market Cap

    28.14M

  • Enterprise Value

    29.51M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.57

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -66.82%

  • Return on Equity (ttm)

    -252.53%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -22.7M

  • Diluted EPS (ttm)

    -1.6900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.54M

  • Total Debt/Equity (mrq)

    72.10%

  • Levered Free Cash Flow (ttm)

    -8.91M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

1.5600 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: